Zhou Yuebiao, Garrigues Star L, Villemure Elisia, Ishisoko Noriko, Nguyen Huy Q, Hamidi Nikkia K, Vogt Rebecca, Wang Yong, Blake Robert A, Rudolph Joachim, Nilewski Christian
Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States.
ACS Med Chem Lett. 2024 Nov 15;15(12):2158-2163. doi: 10.1021/acsmedchemlett.4c00445. eCollection 2024 Dec 12.
Stabilization of cereblon (CRBN)/neosubstrate complexes with molecular glues followed by degradation of those neosubstrates is an emerging strategy in drug discovery with compelling potential to target certain proteins that were previously considered to be undruggable. In this context, the discovery of novel CRBN ligands is an important area of ongoing research that holds promise to expand the scope of proteins that can be targeted through this mode of action. Herein, we describe the synthesis and evaluation of CRBN ligands featuring heteroaryl glutarimide and dihydrouracil scaffolds. We identified a subset of heteroaryl glutarimides exhibiting potent CRBN binding and increased chemical stability in cell culture media compared with traditional immunomodulatory drugs (IMiDs). This indicates that the scaffolds described herein could become useful starting points for the discovery of novel molecular glue degraders.
利用分子胶稳定大脑神经酰胺(CRBN)/新底物复合物,随后降解这些新底物,这是药物研发中一种新兴策略,对于靶向某些以前被认为不可成药的蛋白质具有巨大潜力。在此背景下,发现新型CRBN配体是正在进行的研究的一个重要领域,有望扩大可通过这种作用方式靶向的蛋白质范围。本文中,我们描述了具有杂芳基戊二酰亚胺和二氢尿嘧啶支架的CRBN配体的合成与评估。我们鉴定出一组杂芳基戊二酰亚胺,与传统免疫调节药物(IMiDs)相比,它们在细胞培养基中表现出强大的CRBN结合能力和更高的化学稳定性。这表明本文所述的支架可能成为发现新型分子胶降解剂的有用起点。